Mid- to Long-term Outcomes and Survivorship of the Salto and Salto-Talaris Total Ankle Replacement Implants A Systematic Review.

IF 2.1
Jared Rubin, Alexander Tham, Ryan Rutherford, Michael Allen, Thomas Bieganowski, James J Butler, Akram Habibi, Kevin A Schafer, Raymond J Walls, John G Kennedy
{"title":"Mid- to Long-term Outcomes and Survivorship of the Salto and Salto-Talaris Total Ankle Replacement Implants A Systematic Review.","authors":"Jared Rubin, Alexander Tham, Ryan Rutherford, Michael Allen, Thomas Bieganowski, James J Butler, Akram Habibi, Kevin A Schafer, Raymond J Walls, John G Kennedy","doi":"10.1177/19386400261426062","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundThe purpose of this systematic review is to evaluate the mid-term to long-term clinical outcomes, physical exam findings, radiographic findings, implant survivorship, and complications between the Salto and Salto-Talaris total ankle replacement (TAR) implant designs for the treatment of end-stage arthritis.MethodsDuring September 2025, the PubMed, EMBASE, and Cochrane library databases were systematically reviewed to identify clinical studies examining outcomes and survivorship following TAR with Salto or Salto-Talaris implants. Of note, most included studies were non-comparative case series.ResultsFifteen studies comprising 1196 patients (1221 ankles) who underwent TAR with Salto or Salto-Talaris implants were included. The weighed mean follow-up time for Salto and Salto-Talaris implant patients was 86.4 ± 24.9 and 73.6 ± 23.5 months, respectively. The weighted mean American Orthopaedic Foot and Ankle Society score increased 42.6 ± 16.8 points for the Salto implant cohort and 28.1 ± 15.1 points for the Salto-Talaris implant cohort. For patients who received the Salto implant, 33 (6.8%) ankles required revisions at a weighted mean time of 4.8 ± 1.4 years. Survivorship of the Salto implant at 5- and 10-year follow-up was 92% and 89%, respectively. For patients who underwent the Salto-Talaris implant, 27 (3.7%) ankles required revisions at a weighted mean time of 3.6 ± 2.5 years. Survivorship of the Salto-Talaris implant at 5- and 10-year follow-up was 97% and 92%, respectively.ConclusionsMid-term and long-term follow-ups for patients who received either Salto or Salto-Talaris implants demonstrated improvements in clinical outcomes, radiographic findings, range of motion, and implant survivorship. Overall, both implants provided favorable and largely comparable performance profiles, with low rates of clinical complications and revisions. The absence of formal comparative statistical analyses and head-to-head studies prevents definitive conclusions regarding implant superiority. Further prospective, comparative studies are warranted to establish which implant offers superior longevity for the treatment of end-stage ankle arthritis.Levels of EvidenceIV, systematic review.</p>","PeriodicalId":73046,"journal":{"name":"Foot & ankle specialist","volume":" ","pages":"19386400261426062"},"PeriodicalIF":2.1000,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Foot & ankle specialist","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/19386400261426062","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

BackgroundThe purpose of this systematic review is to evaluate the mid-term to long-term clinical outcomes, physical exam findings, radiographic findings, implant survivorship, and complications between the Salto and Salto-Talaris total ankle replacement (TAR) implant designs for the treatment of end-stage arthritis.MethodsDuring September 2025, the PubMed, EMBASE, and Cochrane library databases were systematically reviewed to identify clinical studies examining outcomes and survivorship following TAR with Salto or Salto-Talaris implants. Of note, most included studies were non-comparative case series.ResultsFifteen studies comprising 1196 patients (1221 ankles) who underwent TAR with Salto or Salto-Talaris implants were included. The weighed mean follow-up time for Salto and Salto-Talaris implant patients was 86.4 ± 24.9 and 73.6 ± 23.5 months, respectively. The weighted mean American Orthopaedic Foot and Ankle Society score increased 42.6 ± 16.8 points for the Salto implant cohort and 28.1 ± 15.1 points for the Salto-Talaris implant cohort. For patients who received the Salto implant, 33 (6.8%) ankles required revisions at a weighted mean time of 4.8 ± 1.4 years. Survivorship of the Salto implant at 5- and 10-year follow-up was 92% and 89%, respectively. For patients who underwent the Salto-Talaris implant, 27 (3.7%) ankles required revisions at a weighted mean time of 3.6 ± 2.5 years. Survivorship of the Salto-Talaris implant at 5- and 10-year follow-up was 97% and 92%, respectively.ConclusionsMid-term and long-term follow-ups for patients who received either Salto or Salto-Talaris implants demonstrated improvements in clinical outcomes, radiographic findings, range of motion, and implant survivorship. Overall, both implants provided favorable and largely comparable performance profiles, with low rates of clinical complications and revisions. The absence of formal comparative statistical analyses and head-to-head studies prevents definitive conclusions regarding implant superiority. Further prospective, comparative studies are warranted to establish which implant offers superior longevity for the treatment of end-stage ankle arthritis.Levels of EvidenceIV, systematic review.

Salto和Salto- talaris全踝关节置换术植入物的中长期疗效和生存率:系统综述。
本系统综述的目的是评估Salto和Salto- talaris全踝关节置换术(TAR)植入物治疗终末期关节炎的中期至长期临床结果、体格检查结果、影像学表现、植入物存活率和并发症。方法在2025年9月,系统地回顾PubMed、EMBASE和Cochrane数据库,以确定使用Salto或Salto- talaris植入物进行TAR后疗效和生存率的临床研究。值得注意的是,大多数纳入的研究是非比较病例系列。结果纳入15项研究,包括1196例(1221踝关节)使用Salto或Salto- talaris植入物行TAR的患者。Salto和Salto- talaris种植体患者的加权平均随访时间分别为86.4±24.9和73.6±23.5个月。美国骨科足踝学会(American Orthopaedic Foot and Ankle Society)的加权平均评分Salto组增加42.6±16.8分,Salto- talaris组增加28.1±15.1分。在接受Salto植入的患者中,33(6.8%)个踝关节需要修复,加权平均时间为4.8±1.4年。在5年和10年随访中,Salto种植体的存活率分别为92%和89%。在接受Salto-Talaris植入的患者中,27例(3.7%)踝关节需要修复,加权平均时间为3.6±2.5年。在5年和10年随访中,Salto-Talaris种植体的存活率分别为97%和92%。中期和长期随访表明,接受Salto或Salto- talaris植入物的患者在临床结果、影像学表现、活动范围和植入物存活方面均有改善。总的来说,这两种植入物都提供了良好的性能,并且在很大程度上具有可比性,临床并发症和修复率低。缺乏正式的比较统计分析和面对面的研究阻止了关于植入物优越性的明确结论。进一步的前瞻性比较研究是有必要的,以确定哪种植入物对终末期踝关节关节炎的治疗具有更长的寿命。证据水平,系统评价。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书